Antibiotice S.A. Logo

Antibiotice S.A.

Develops and manufactures generic medicines and APIs, specializing in anti-infectives.

ATB | RO

Overview

Corporate Details

ISIN(s):
ROATBIACNOR9
LEI:
315700P5G4O1L6GLMS02
Country:
Romania
Address:
VALEA LUPULUI, 707410 IAȘI
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Antibiotice S.A. is a pharmaceutical company specializing in the development and manufacturing of generic medicines. With a history of over 65 years, the company produces a diverse portfolio of products for human use, including finished dosage forms and Active Pharmaceutical Ingredients (APIs). Its offerings have a strong focus on anti-infectives, such as penicillin-derived products. The company operates eight GMP-certified manufacturing lines and holds U.S. FDA approvals for key products, including Nystatin (API), Ampicillin for injection, and Nafcillin. Antibiotice is committed to making valuable medicines accessible and affordable for patients and healthcare professionals, driven by continuous investment in research, quality, and the modernization of its manufacturing technologies.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-11 15:37
ISS
Raport curent de informare a investitorilor
Romanian 1.0 MB
2025-11-07 07:37
Report Publication Announcement
Raport curent de informare a investitorilor
Romanian 546.9 KB
2025-11-06 12:52
Post-Annual General Meeting Information
Raport curent de informare a investitorilor
Romanian 643.5 KB
2025-11-06 12:49
Post-Annual General Meeting Information
Raport curent de informare a investitorilor
Romanian 1.0 MB
2025-11-05 10:20
Pre-Annual General Meeting Information
Raport curent de informare a investitorilor
Romanian 291.4 KB
2025-10-03 11:39
Pre-Annual General Meeting Information
Convocarea adunarii generale a actionarilor - RC11
Romanian 1.4 MB
2025-10-03 11:38
Pre-Annual General Meeting Information
Raport curent de informare a investitorilor
Romanian 1.7 MB
2025-10-01 12:53
Pre-Annual General Meeting Information
Raport curent de informare a investitorilor
Romanian 2.4 MB
2025-09-23 08:35
Pre-Annual General Meeting Information
Convocarea adunarii generale a actionarilor - RC11
Romanian 1.4 MB
2025-09-17 15:12
Post-Annual General Meeting Information
Raport curent de informare a investitorilor
Romanian 949.8 KB
2025-09-04 12:29
Notice of Dividend Amount
Plata dividend - RC17
Romanian 2.1 MB
2025-08-13 12:27
Pre-Annual General Meeting Information
Convocarea adunarii generale a actionarilor - RC11
Romanian 1.4 MB
2025-08-06 12:40
Report Publication Announcement
Raport curent de informare a investitorilor
Romanian 137.7 KB
2025-07-24 12:07
Pre-Annual General Meeting Information
Convocarea adunarii generale a actionarilor - RC11
Romanian 1.6 MB
2025-07-09 12:28
Board/Management Information
Raport curent de informare a investitorilor
Romanian 491.4 KB

Automate Your Workflow. Get a real-time feed of all Antibiotice S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Antibiotice S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Antibiotice S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Mereo BioPharma Group plc Logo
A clinical-stage biopharma developing and commercializing novel therapies for rare diseases.
United States of America
MREO
Mersana Therapeutics, Inc. Logo
Developing innovative antibody-drug conjugates using proprietary platforms to treat cancer.
United States of America
MRSN
Merus N.V. Logo
Develops multispecific antibody therapies that harness the immune system to fight cancer.
United States of America
MRUS
MESOBLAST LTD Logo
Develops off-the-shelf cellular medicines for complex inflammatory and chronic diseases.
United States of America
MESO
Metagenomi, Inc. Logo
Discovering novel gene editing tools from nature for curative genetic medicines.
United States of America
MGX
MetaVia Inc. Logo
A clinical-stage biotech developing novel drugs for cardiometabolic diseases like obesity and MASH.
United States of America
MTVA
Metsera, Inc. Logo
Develops potent, long-acting oral & injectable therapies for obesity & metabolic diseases.
United States of America
MTSR
Mezzion Pharma Co., Ltd. Logo
Develops and out-licenses novel therapeutics like udenafil, with a focus on rare diseases.
South Korea
140410
MFC Co., Ltd. Logo
A GMP-certified CDMO/CMO developing and manufacturing APIs for the global pharma sector.
South Korea
432980
Milestone Pharmaceuticals Inc. Logo
Developing a self-administered nasal spray for at-home treatment of acute cardiac events.
United States of America
MIST

Talk to a Data Expert

Have a question? We'll get back to you promptly.